Haloarene derivatives of carbamazepine with reduced bioactivation liabilities: 2-monohalo and 2,8-dihalo derivatives

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9773-9784

  Elliott, Emma Claire ^a,b   Regan, Sophie L ^a,b   Maggs, James L ^a,b   Bowkett, Elizabeth R ^a   Parry, Laura J ^a,c   Williams, Dominic P ^a,b   Park, B Kevin ^a   Stachulski, Andrew V ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNILEVER RESEARCH   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMOCARBAMAZEPINE; 2 CHLORO 10,11 DIHYDRO 5H DIBENZ[B,F ]AZEPINE; 2 CHLORO 5H DIBENZ[B,F ]AZEPINE; 2 CHLOROCARBAMAZEPINE; 2 FLUOROCARBAMAZEPINE; 2,8 DIBROMOCARBAMAZEPINE; 2,8 DICHLOROCARBAMAZEPINE; 2,8 DIFLUOROCARBAMAZEPINE; CARBAMAZEPINE; DIBENZAZEPINE DERIVATIVE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DEHALOGENATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EPOXIDATION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER CELL; MALE; METABOLITE; NONHUMAN; RAT;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; GLUTATHIONE; HALOGENS; HEPATOCYTES; HUMANS; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; RATS; RATS, WISTAR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84870014766     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301013n     Document Type: Article

References (81)

1. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A. K.; Walley, T. J.; Farrar, K.; Park, B. K.; Breckenridge, A. M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients BMJ (Br. Med. J.) 2004, 329, 12-19
2. McCormack, M.; Alfirevic, A.; Bourgeois, S.; Farrell, J. J.; Kasperavičiute, D.; Carrington, M.; Sills, G. J.; Marson, T.; Jia, X.; de Bakker, P. I.; Chinthapalli, K.; Molokhia, M.; Johnson, M. R.; O'Connor, G. D.; Chaila, E.; Alhusaini, S.; Shianna, K. V.; Radtke, R. A.; Heinzen, E. L.; Walley, N.; Pandolfo, M.; Pichler, W.; Park, B. K.; Depondt, C.; Sisodiya, S. M.; Goldstein, D. B.; Deloukas, P.; Delanty, N.; Cavalleri, G. L.; Pirmohamed, M. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans N. Engl. J. Med. 2011, 364, 1134-1143
3. Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T. A.; Kalgutkar, A. S.; Aleo, M. D. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 2011, 24, 1345-1410
4. Park, B. K.; Boobis, A.; Clarke, S.; Goldring, C. E.; Jones, D.; Kenna, J. G.; Lambert, C.; Laverty, H. G.; Naisbitt, D. J.; Nelson, S.; Nicoll-Griffith, D. A.; Obach, R. S.; Routledge, P.; Smith, D. A.; Tweedie, D. J.; Vermeulen, N.; Williams, D. P.; Wilson, I. D.; Baillie, T. A. Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discovery 2011, 10, 292-306
5. Albani, F.; Riva, R.; Baruzzi, A. Carbamazepine clinical pharmacology: a review Pharmacopsychiatry 1995, 28, 235-244
6. Syn, W. K.; Naisbitt, D. J.; Holt, A. P.; Pirmohamed, M.; Mutimer, D. J. Carbamazepine-induced acute liver failure as part of the DRESS syndrome Int. J. Clin. Pract. 2005, 59, 988-991
7. Bjornsson, E. Hepatotoxicity associated with antiepileptic drugs Acta Neurol. Scand. 2008, 118, 281-290
8. Friedmann, P. S.; Strickland, I.; Pirmohamed, M.; Park, B. K. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine Arch. Dermatol. 1994, 130, 598-604
9. Pirmohamed, M.; Kitteringham, N. R.; Guenthner, T. M.; Breckenridge, A. M.; Park, B. K. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro Biochem. Pharmacol. 1992, 43, 1675-1682
10. Pirmohamed, M.; Kitteringham, N. R.; Breckenridge, A. M.; Park, B. K. The effect of enzyme induction on the cytochrome P450-mediated bioactivation of carbamazepine by mouse liver microsomes Biochem. Pharmacol. 1992, 44, 2307-2314
11. Lertratanangkoon, K.; Horning, M. G. Metabolism of carbamazepine Drug Metab. Dispos. 1982, 10, 1-10
12. Eichelbaum, M.; Tomson, T.; Tybring, G.; Bertilsson, L. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects Clin. Pharmacokinet. 1985, 10, 80-90
13. Maggs, J. L.; Pirmohamed, M.; Kitteringham, N. R.; Park, B. K. Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry Drug Metab. Dispos. 1997, 25, 275-280
14. Lillibridge, J. H.; Amore, B. M.; Slattery, J. T.; Kalhorn, T. F.; Nelson, S. D.; Finnell, R. H.; Bennett, G. D. Protein-reactive metabolites of carbamazepine in mouse liver microsomes Drug Metab. Dispos. 1996, 24, 509-514
15. Madden, S.; Maggs, J. L.; Park, B. K. Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s) Drug Metab. Dispos. 1996, 24, 469-479
16. Pearce, R. E.; Lu, W.; Wang, Y.; Uetrecht, J. P.; Correia, M. A.; Leeder, J. S. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine Drug Metab. Dispos. 2008, 36, 1637-1349
17. Furst, S. M.; Uetrecht, J. P. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils Biochem. Pharmacol. 1993, 45, 1267-1275
18. Pearce, R. E.; Uetrecht, J. P.; Leeder, J. S. Pathways of carbamazepine bioactivation in vitro: II. The role of human cytochrome P450 enzymes in the formation of 2-hydroxyiminostilbene Drug Metab. Dispos. 2005, 33, 1819-1826
19. Bu, H. Z.; Kang, P.; Deese, A. J.; Zhao, P.; Pool, W. F. Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine Drug Metab. Dispos. 2005, 33, 1920-1924
20. Bu, H. Z.; Zhao, P.; Dalvie, D. K.; Pool, W. F. Identification of primary and sequential bioactivation pathways of carbamazepine in human liver microsomes using liquid chromatography/tandem mass spectrometry Rapid Commun. Mass Spectrom. 2007, 21, 3317-3322
21. Hartz, R. A.; Ahuja, V. T.; Zhuo, X.; Mattson, R. J.; Denhart, D. J.; Deskus, J. A.; Vrudhula, V. M.; Pan, S.; Ditta, J. L.; Shu, Y. Z.; Grace, J. E.; Lentz, K. A.; Lelas, S.; Li, Y. W.; Molski, T. F.; Krishnananthan, S.; Wong, H.; Qian-Cutrone, J.; Schartman, R.; Denton, R.; Lodge, N. J.; Zaczek, R.; Macor, J. E.; Bronson, J. J. A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6- (difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5 dihydropyrazine-2- carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist J. Med. Chem. 2009, 52, 7653-7668
22. Ambrósio, A. F.; Soares-da-Silva, P.; Carvalho, C. M.; Carvalho, A. P. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024 Neurochem. Res. 2002, 27, 121-130
23. Wu, Y.; Sanderson, J. P.; Farrell, J.; Drummond, N. S.; Hanson, A.; Bowkett, E.; Berry, N.; Stachulski, A. V.; Clarke, S. E.; Pichler, W. J.; Pirmohamed, M.; Park, B. K.; Naisbitt, D. J. Activation of T cells by carbamazepine and carbamazepine metabolites J. Allergy Clin. Immunol. 2006, 118, 233-241
24. Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of fluorine-containing drugs Annu. Rev. Pharmacol. Toxicol. 2001, 41, 443-470
25. Ma, S.; Zhu, M. Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites Chem.-Biol. Interact. 2009, 179, 25-37
26. Morgan, P.; Maggs, J. L.; Bulman-Page, P. C.; Hussain, F.; Park, B. K. The metabolism of 2- and 4-fluoro-17 β-oestradiol in the rat and its implications for oestrogen carcinogenesis Biochem. Pharmacol. 1992, 43, 985-993
27. Morgan, P.; Maggs, J. L.; Page, P. C.; Park, B. K. Oxidative dehalogenation of 2-fluoro-17α-ethynyloestradiol in vivo. A distal structure-metabolism relationship of 17 α-ethynylation Biochem. Pharmacol. 1992, 44, 1717-1724
28. Chen, H.; Shockcor, J.; Chen, W.; Espina, R.; Gan, L. S.; Mutlib, A. E. Delineating novel metabolic pathways of DPC 963, a non-nucleoside reverse transcriptase inhibitor, in rats. Characterization of glutathione conjugates of postulated oxirene and benzoquinone imine intermediates by LC/MS and LC/NMR Chem. Res. Toxicol. 2002, 15, 388-399
29. Kricka, L. J.; Ledwith, A. Dibenz[ b, f ]azepines and related ring systems Chem. Rev. 1974, 74, 101-123
30. Varma, R. S.; Whisenant, L. K.; Boykin, D. W. Synthesis of some substituted 5 H -dibenz[ b, f ]azepines as potent antimalarials J. Med. Chem. 1969, 12, 913-914
31. Schindler, W. New N-heterocyclic compounds. U.S. Patent U.S. 2,948,718, 1960.
32. Theobald, W.; Wilhelmi, G.; Krupp, P. Analgesic and anticonvulsant activity of derivatives of dibenz(b, f)azepine. In Pain; Soulairac, A.; Cahn, J.; Charpentier, J., Eds.; Academic Press: London, U.K., 1968; pp 239-249.
33. Jørgensen, T. K.; Andersen, K. E.; Lau, J.; Madsen, P.; Huusfeldt, P. O. Synthesis of substituted 10,11-dihydro-5 H -dibenz[ b,f ]azepines: key synthons in syntheses of pharmaceutically active compounds J. Heterocycl. Chem. 1999, 36, 57-64
34. Schindler, W.; Blattner, H. Über derivate des iminodibenzyls iminostilben-derivate Helv. Chim. Acta 1961, 44, 753-762
35. Smith, K.; James, D. M.; Mistry, A. G.; Bye, M. R.; Faulkner, D. J. A new method for the bromination of carbazoles, β-carbolines and iminodibenzyls by use of N- bromosuccinimide and silica gel Tetrahedron 1992, 48, 7479-7488
36. Axtell, H. C.; McHugh, K. B.; Cann, M. C. Reaction of 8H-furo[3,4-d]dibenz[b,f]azepine and 9H-tribenz[b,d,f]azepine with t-butyl hypochlorite and silver trifluoroacetate. Attempts to form a long-lived aromatic nitrenium ion Heterocycles 1995, 41, 431-438
37. Tokmakov, G. P.; Grandberg, I. I. Rearrangement of 1-arylindoles to 5H-dibenz[b,f]azepines Tetrahedron 1995, 51, 2091-2098
38. Elliott, E.-C.; Bowkett, E. R.; Maggs, J. L.; Bacsa, J.; Park, B. K.; Regan, S. L.; O'Neill, P. M.; Stachulski, A. V. Convenient syntheses of benzo-fluorinated iminostilbenes: rearrangements of isatins, acridines and indoles Org. Lett. 2011, 13, 5592-5595
39. Kenny, J. R.; Maggs, J. L.; Tettey, J. N.; Harrell, A. W.; Parker, S. G.; Clarke, S. E.; Park, B. K. Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): relation to species differences in hepatotoxicity Drug Metab. Dispos. 2005, 33, 271-281
40. Williams, D. P.; Antoine, D. J.; Butler, P. J.; Jones, R.; Randle, L.; Payne, A.; Howard, M.; Gardner, I.; Blagg, J.; Park, B. K. The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore J. Pharmacol. Exp. Ther. 2007, 322, 1208-1220
41. Graham, E. E.; Walsh, R. J.; Hirst, C. M.; Maggs, J. L.; Martin, S.; Wild, M. J.; Wilson, I. D.; Harding, J. R.; Kenna, J. G.; Peter, R. M.; Williams, D. P.; Park, B. K. Identification of the thiophene ring of methapyrilene as a novel bioactivation-dependent hepatic toxicophore J. Pharmacol. Exp. Ther. 2008, 326, 657-671
42. Matei, S. L. Dihydrodibenzazepine derivate. Rom., 81554, 29 Apr 1983.
43. 2O, efficient halogenating systems for aromatics J. Am. Chem. Soc. 2004, 126, 15770-15776
44. Kricka, L. J.; Ledwith, A. Reactions of condensed N -heteroaromatic molecules. Part II. Electrophilic substitution of N -acetylcarbazole, N -acetyl-l0,11-dihydrodibenz[ b,f ]azepine, and derivatives J. Chem. Soc., Perkin Trans. 1 1973, 859-863
45. Kricka, L. J.; Ledwith, A. Dibenz[ b,f ]azepines and related systems Chem. Rev. 1974, 74, 101-123
46. Elliot, E.-C. Ph.D. thesis, University of Liverpool, 2011.
47. Raml, W.; Eichberger, G. Process for the preparation of carbamazepine from 5H-dibenz[b,f]azepine and phosgene with subsequent ammonium hydroxide amidation of the carbonyl chloride intermediate. DE 4421294, 21 Dec 1995.
48. 3 J. Labelled Compd. Radiopharm. 2009, 52, 166-172
49. Che, D.; Corelli-Rennie, N.; Guntoori, B. R.; Faught, J. Process for the preparation of oxcarbazepine and related derivatives. US20050282797, 22 Dec 2005.
50. Schweim, H. G. Reactions of N-or N ′-blocked N -acylureas with amines Arch. Pharm. 1987, 320, 430-437
51. Analogously, trichloroacetyl isocyanate has been used to convert alcohols to carbamates: Narina, S. V.; Kumar, T. S.; George, S.; Sudalai, A. Tetrahedron Lett. 2007, 48, 65-68
52. Eckardt, R.; Jaensch, H.-J. Process for the preparation of 5H-dibenz[b,f]azepine-5-carboxamide from iminostilbene and alkali cyanates. DE 4307181, 10 Nov 1994.
53. Durant, G. J. Improved synthesis of N, N-diarylureas Chem. Ind. (London, U. K.) 1965, 1428-1429
54. Breyer-Pfaff, U.; Wachsmuth, H. Tertiary N -glucuronides of clozapine and its metabolite desmethylclozapine in patient urine Drug Metab. Dispos. 2001, 29, 1343-1348
55. Mahajan, M. K.; Evans, C. A. Dual negative precursor ion scan approach for rapid detection of glutathione conjugates using liquid chromatography/tandem mass spectrometry Rapid Commun. Mass Spectrom. 2008, 22, 1032-1040
56. Kitteringham, N. R.; Davis, C.; Howard, N.; Pirmohamed, M.; Park, B. K. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene J. Pharmacol. Exp. Ther. 1996, 278, 1018-1027
57. Maggs, J. L.; Williams, D.; Pirmohamed, M.; Park, B. K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man J. Pharmacol. Exp. Ther. 1995, 275, 1463-1475
58. +-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs Xenobiotica 1995, 25, 291-301
59. Breyer-Pfaff, U.; Becher, B.; Nusser, E.; Nill, K.; Baier-Weber, B.; Zaunbrecher, D.; Wachsmuth, H.; Prox, A. Quaternary N -glucuronides of 10-hydroxylated amitriptyline metabolites in human urine Xenobiotica 1990, 20, 727-738
60. Potter, J. M.; Donnelly, A. Carbamazepine-10,11-epoxide in therapeutic drug monitoring Ther. Drug Monit. 1998, 20, 652-657
61. Wen, B.; Ma, L.; Nelson, S. D.; Zhu, M. High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry Anal. Chem. 2008, 80, 1788-1799
62. 19F-n.m.r. spectroscopy to the identification of dog urinary metabolites of imirestat, a spirohydantoin aldose reductase inhibitor Xenobiotica 1992, 22, 775-787
63. Dear, G. J.; Ismail, I. M.; Mutch, P. J.; Plumb, R. S.; Davies, L. H.; Sweatman, B. C. Urinary metabolites of a novel quinoxaline non-nucleoside reverse transcriptase inhibitor in rabbit, mouse and human: identification of fluorine NIH shift metabolites using NMR and tandem MS Xenobiotica 2000, 30, 407-426
64. 3H]17β-oestradiol in the rat: ring-A dibromination blocks male-specific 15α-hydroxylation and catechol formation J. Steroid Biochem. Mol. Biol. 1992, 42, 77-85
65. Li, C.; Chauret, N.; Trimble, L. A.; Nicoll-Griffith, D. A.; Silva, J. M.; MacDonald, D.; Perrier, H.; Yergey, J. A.; Parton, T.; Alexander, R. P.; Warrellow, G. J. Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization Drug Metab. Dispos. 2001, 29, 232-241
66. Nielsen, K. K.; Flinois, J. P.; Beaune, P.; Brøsen, K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways J. Pharmacol. Exp. Ther. 1996, 277, 1659-1664
67. Koerts, J.; Velraeds, M. M.; Soffers, A. E.; Vervoort, J.; Rietjens, I. M. Influence of substituents in fluorobenzene derivatives on the cytochrome P450-catalyzed hydroxylation at the adjacent ortho aromatic carbon center Chem. Res. Toxicol. 1997, 10, 279-288
68. Mutlib, A. E.; Chen, H.; Nemeth, G. A.; Markwalder, J. A.; Seitz, S. P.; Gan, L. S.; Christ, D. D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz Drug Metab. Dispos. 1999, 27, 1319-1333
69. Yang, T. J.; Krausz, K. W.; Sai, Y.; Gonzalez, F. J.; Gelboin, H. V. Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism Drug Metab. Dispos. 1999, 27, 102-109
70. Wind, M.; Spickermann, J.; Schleimer, M.; Donzelli, M.; Gebhardt, K.; Sturm-Haurany, R.; Klauer, D.; Fullhardt, P.; Schmitt-Hoffmann, A. Investigation of low-abundant in vitro metabolites of stable isotope-labelled BAL4815 by accurate mass capillary-LC-ESI-qTof-MS and MS/MS J. Mass Spectrom. 2006, 41, 903-910
71. Kenny, J. R.; Maggs, J. L.; Meng, X.; Sinnott, D.; Clarke, S. E.; Park, B. K.; Stachulski, A. V. Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac J. Med. Chem. 2004, 47, 2816-2825
72. Maggs, J. L.; Naisbitt, D. J.; Tettey, J. N.; Pirmohamed, M.; Park, B. K. Metabolism of lamotrigine to a reactive arene oxide intermediate Chem. Res. Toxicol. 2000, 13, 1075-1081
73. Lipkind, G. M.; Fozzard, H. A. Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore Mol. Pharmacol. 2010, 78, 631-638
74. Magnusson, M. O.; Dahl, M. L.; Cederberg, J.; Karlsson, M. O.; Sandström, R. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin Clin. Pharmacol. Ther. 2008, 84, 52-62
75. Beutler, A. S.; Li, S.; Nicol, R.; Walsh, M. J. Carbamazepine is an inhibitor of histone deacetylases Life Sci. 2005, 76, 3107-3115
76. Wu, Y.; Shi, X.; Liu, Y.; Zhang, X.; Wang, J.; Luo, X.; Wen, A. Histone deacetylase 1 is required for carbamazepine-induced CYP3A4 expression J. Pharm. Biomed. Anal. 2012, 58, 78-82
77. Stettner, M.; Krämer, G.; Strauss, A.; Kvitkina, T.; Ohle, S.; Kieseier, B. C.; Thelen, P. Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer Eur. J. Cancer Prev. 2012, 21, 55-64
78. Ortore, G.; Di Colo, F.; Martinelli, A. Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities J. Chem. Inf. Model. 2009, 49, 2774-2785
79. Seglen, P. O. Preparation of isolated rat liver cells Methods Cell Biol. 1976, 13, 29-83
80. max of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product Br. J. Clin. Pharmacol. 1998, 45, 241-246
81. Pattanaik, S.; Hota, D.; Prabhakar, S.; Kharbanda, P.; Pandhi, P. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients Phytother. Res. 2009, 23, 1281-1286